Upstream Bio, Inc.
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 clinical development for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps, and in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporat… Read more
Upstream Bio, Inc. (UPB) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.059x
Based on the latest financial reports, Upstream Bio, Inc. (UPB) has a cash flow conversion efficiency ratio of -0.059x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-22.24 Million) by net assets ($378.58 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Upstream Bio, Inc. - Cash Flow Conversion Efficiency Trend (2022–2024)
This chart illustrates how Upstream Bio, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Upstream Bio, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Upstream Bio, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jw Pharmac
KO:001060
|
0.132x |
|
Sichuan Goldstone Orient New Material Equipment Co Ltd
SHE:300434
|
0.063x |
|
Matrix Service Co
NASDAQ:MTRX
|
0.054x |
|
Village Farms International Inc
NASDAQ:VFF
|
0.084x |
|
Jinan High tech Development Co Ltd
SHG:600807
|
-0.013x |
|
Turners Automotive Group Ltd
AU:TRA
|
-0.102x |
|
Genomictree Inc.
KQ:228760
|
-0.021x |
|
Gruvaktiebolaget Viscaria
ST:VISC
|
-0.021x |
Annual Cash Flow Conversion Efficiency for Upstream Bio, Inc. (2022–2024)
The table below shows the annual cash flow conversion efficiency of Upstream Bio, Inc. from 2022 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $469.85 Million | $-59.17 Million | -0.126x | -140.89% |
| 2023-12-31 | $-123.13 Million | $-37.93 Million | 0.308x | +71.91% |
| 2022-12-31 | $-106.16 Million | $-19.02 Million | 0.179x | -- |